Nuria Kotecki

2.8k total citations
68 papers, 592 citations indexed

About

Nuria Kotecki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nuria Kotecki has authored 68 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Nuria Kotecki's work include Cancer Immunotherapy and Biomarkers (19 papers), Brain Metastases and Treatment (10 papers) and Cancer Genomics and Diagnostics (9 papers). Nuria Kotecki is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Brain Metastases and Treatment (10 papers) and Cancer Genomics and Diagnostics (9 papers). Nuria Kotecki collaborates with scholars based in Belgium, France and United States. Nuria Kotecki's co-authors include Ahmad Awada, Nicolas Penel, Sophie Cousin, Agnès Ducoulombier, Evandro de Azambuja, Fahed Zaïri, Daniel Devriendt, Matteo Lambertini, Émilie Le Rhun and Florence Lefranc and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Nuria Kotecki

61 papers receiving 583 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nuria Kotecki Belgium	13	324	284	137	101	98	68	592
Gil Awada Belgium	15	450 1.4×	151 0.5×	176 1.3×	156 1.5×	132 1.3×	58	691
Ramón Palmero Spain	14	384 1.2×	328 1.2×	159 1.2×	42 0.4×	49 0.5×	50	646
Hidenori Mizugaki Japan	14	400 1.2×	231 0.8×	207 1.5×	72 0.7×	38 0.4×	40	710
A.R. Abdul Razak Canada	11	435 1.3×	283 1.0×	211 1.5×	105 1.0×	37 0.4×	26	760
Andy Kaempf United States	12	227 0.7×	138 0.5×	181 1.3×	135 1.3×	73 0.7×	50	530
Ashraf S. Mahmoud-Ahmed United States	10	242 0.7×	226 0.8×	135 1.0×	83 0.8×	117 1.2×	12	572
Kwai Han Yoo South Korea	15	270 0.8×	210 0.7×	183 1.3×	48 0.5×	90 0.9×	50	588
Elio Gregory Pizzutilo Italy	10	428 1.3×	266 0.9×	152 1.1×	55 0.5×	54 0.6×	18	651
Daniela Morales-Espinosa Spain	12	276 0.9×	190 0.7×	206 1.5×	56 0.6×	44 0.4×	25	534
Norikazu Matsuo Japan	14	442 1.4×	376 1.3×	95 0.7×	153 1.5×	21 0.2×	40	677

Countries citing papers authored by Nuria Kotecki

Since Specialization

Citations

This map shows the geographic impact of Nuria Kotecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nuria Kotecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nuria Kotecki more than expected).

Fields of papers citing papers by Nuria Kotecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nuria Kotecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nuria Kotecki. The network helps show where Nuria Kotecki may publish in the future.

Co-authorship network of co-authors of Nuria Kotecki

This figure shows the co-authorship network connecting the top 25 collaborators of Nuria Kotecki. A scholar is included among the top collaborators of Nuria Kotecki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nuria Kotecki. Nuria Kotecki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Valiente, Manuel, Carey K. Anders, Nuria Kotecki, et al.. (2025). The evolving landscape of brain metastasis: volume II. Trends in cancer. 12(2). 116–146.

Heymach, John V., Nuria Kotecki, Hans Prenen, et al.. (2023). 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation. Annals of Oncology. 34. S468–S468. 10 indexed citations

Rodón, Jordi, Daniel Shao-Weng Tan, Ignacio Garrido‐Laguna, et al.. (2023). Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO Open. 8(4). 101584–101584. 8 indexed citations

Kotecki, Nuria, Sylvie Rottey, Elena Garralda, et al.. (2023). 1048P Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer. Annals of Oncology. 34. S635–S635. 1 indexed citations

Champiat, Stéphane, Philippe A. Cassier, Nuria Kotecki, et al.. (2023). Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors. Cancer Research. 83(7_Supplement). 2129–2129. 2 indexed citations

Kotecki, Nuria, Sylvie Rottey, Elena Garralda, et al.. (2023). Abstract CT258: A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors. Cancer Research. 83(8_Supplement). CT258–CT258. 1 indexed citations

Pinato, David J., Ruth Plummer, Martin Gutierrez, et al.. (2022). 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A654–A654. 3 indexed citations

Prenen, Hans, Thierry Lesimple, Marie E. Robert, et al.. (2022). 734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A766–A766. 2 indexed citations

Harding, James J., Ahmad Awada, Gaël S. Roth, et al.. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer. 11(3). 268–277. 16 indexed citations

10.

Champiat, Stéphane, Martin Wermke, Cécile Vicier, et al.. (2022). 732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial. Annals of Oncology. 33. S877–S878. 1 indexed citations

11.

Marta, Guilherme Nader, Diogo Martins-Branco, Elisa Agostinetto, et al.. (2022). Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO Open. 7(3). 100501–100501. 20 indexed citations

12.

Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations

13.

Chanzá, Nieves Martínez, Philippe Barthélémy, Brieuc Sautois, et al.. (2021). 659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). Annals of Oncology. 32. S683–S683. 5 indexed citations

14.

Tourneau, Christophe Le, Jean‐Pierre Delord, Nuria Kotecki, et al.. (2020). A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours. British Journal of Cancer. 123(10). 1481–1489. 5 indexed citations

15.

Awada, Ahmad, Marianne Paesmans, Michel Moreau, et al.. (2019). Predictive factors for cancer-associated thrombosis in a large retrospective single-center study. Supportive Care in Cancer. 27(4). 1163–1170. 12 indexed citations

16.

Rottey, Sylvie, Philippe Barthélémy, Nuria Kotecki, et al.. (2019). Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies. Anticancer Research. 39(6). 2993–3002. 5 indexed citations

17.

Kotecki, Nuria, et al.. (2016). Contribution of Next-generation Sequencing in a Case of Metastatic Breast Carcinoma with Pulmonary Lesions. 1(1). 1 indexed citations

18.

Kotecki, Nuria, Axel Le Cesne, Emmanuelle Tresch‐Bruneel, et al.. (2016). Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS). Annals of Oncology. 27. vi486–vi486. 4 indexed citations

19.

Kotecki, Nuria & Nicolas Penel. (2016). Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin. Current Opinion in Oncology. 28(5). 437–440. 5 indexed citations

20.

Zaïri, Fahed, et al.. (2010). Complications related to the placement of an intraventricular chemotherapy device. Journal of Neuro-Oncology. 104(1). 247–252. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact